Cargando…

Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk

Objective Epidemiological studies have shown evidence of the effect of genetic variations in the pathogenesis of breast cancer and have suggested a relationship of the disease with genetic polymorphisms. Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV co...

Descripción completa

Detalles Bibliográficos
Autores principales: Felizi, Rogério Tadeu, Veiga, Melissa Gonzalez, Carelli Filho, Ivo, Souto, Ricardo Peres do, Fernandes, César Eduardo, Oliveira, Emerson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316932/
https://www.ncbi.nlm.nih.gov/pubmed/30352460
http://dx.doi.org/10.1055/s-0038-1673366
_version_ 1785067813580308480
author Felizi, Rogério Tadeu
Veiga, Melissa Gonzalez
Carelli Filho, Ivo
Souto, Ricardo Peres do
Fernandes, César Eduardo
Oliveira, Emerson
author_facet Felizi, Rogério Tadeu
Veiga, Melissa Gonzalez
Carelli Filho, Ivo
Souto, Ricardo Peres do
Fernandes, César Eduardo
Oliveira, Emerson
author_sort Felizi, Rogério Tadeu
collection PubMed
description Objective Epidemiological studies have shown evidence of the effect of genetic variations in the pathogenesis of breast cancer and have suggested a relationship of the disease with genetic polymorphisms. Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and other essential extra cellular matrix components, being involved in the tumor cell invasion and metastasis. Our objective was to evaluate the relationship between the MMP-9-1562 C/T polymorphism (rs 3918242) and the risk of developing breast cancer. Methods In this case-control study, the frequency of the MMP-9-1562 C/T polymorphism (rs 3918242) was determined in 148 women with breast cancer and 245 women without the disease. The DNA was extracted from plasma samples, and the gene was amplified by polymerase chain reaction (PCR); the presence of the polymorphism was determined using restriction enzymes. Results After adjusting for confounding variables, we found that the polymorphism was not associated with the occurrence of breast cancer (odds ratio [OR] = 1.159, 95% confidence interval [CI]: 0.6625–1.997, p = 0.5964). We also found no association with more advanced disease, the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2) overexpression, or rate of tumor cell proliferation. Conclusion We did not observe a relationship between MMP-9–1562 C/T polymorphism (rs 3918242) and the occurrence of breast cancer.
format Online
Article
Text
id pubmed-10316932
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Thieme Revinter Publicações Ltda
record_format MEDLINE/PubMed
spelling pubmed-103169322023-07-27 Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk Felizi, Rogério Tadeu Veiga, Melissa Gonzalez Carelli Filho, Ivo Souto, Ricardo Peres do Fernandes, César Eduardo Oliveira, Emerson Rev Bras Ginecol Obstet Objective Epidemiological studies have shown evidence of the effect of genetic variations in the pathogenesis of breast cancer and have suggested a relationship of the disease with genetic polymorphisms. Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and other essential extra cellular matrix components, being involved in the tumor cell invasion and metastasis. Our objective was to evaluate the relationship between the MMP-9-1562 C/T polymorphism (rs 3918242) and the risk of developing breast cancer. Methods In this case-control study, the frequency of the MMP-9-1562 C/T polymorphism (rs 3918242) was determined in 148 women with breast cancer and 245 women without the disease. The DNA was extracted from plasma samples, and the gene was amplified by polymerase chain reaction (PCR); the presence of the polymorphism was determined using restriction enzymes. Results After adjusting for confounding variables, we found that the polymorphism was not associated with the occurrence of breast cancer (odds ratio [OR] = 1.159, 95% confidence interval [CI]: 0.6625–1.997, p = 0.5964). We also found no association with more advanced disease, the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2) overexpression, or rate of tumor cell proliferation. Conclusion We did not observe a relationship between MMP-9–1562 C/T polymorphism (rs 3918242) and the occurrence of breast cancer. Thieme Revinter Publicações Ltda 2018-10 /pmc/articles/PMC10316932/ /pubmed/30352460 http://dx.doi.org/10.1055/s-0038-1673366 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Felizi, Rogério Tadeu
Veiga, Melissa Gonzalez
Carelli Filho, Ivo
Souto, Ricardo Peres do
Fernandes, César Eduardo
Oliveira, Emerson
Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title_full Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title_fullStr Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title_full_unstemmed Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title_short Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk
title_sort association between matrix metallopeptidase 9 polymorphism and breast cancer risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316932/
https://www.ncbi.nlm.nih.gov/pubmed/30352460
http://dx.doi.org/10.1055/s-0038-1673366
work_keys_str_mv AT felizirogeriotadeu associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk
AT veigamelissagonzalez associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk
AT carellifilhoivo associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk
AT soutoricardoperesdo associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk
AT fernandescesareduardo associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk
AT oliveiraemerson associationbetweenmatrixmetallopeptidase9polymorphismandbreastcancerrisk